中國生物製藥(01177.HK)TQG203上市申請獲得受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

中國生物製藥(01177.HK)TQG203上市申請獲得受理

阿思達克 12-14 05:49

中國生物製藥(01177.HK)公布，集團開發的TQG203「注射用重組人凝血因子VIIa」已向國家藥品監督管理局提交上市申請並獲得受理。適應症為抑制物陽性先天性血友病A或B患者以及某些特定類型罕見出血性疾病患者群體出血的治療和外科手術或有創操作出血的防治。

中國生物製藥(01177.HK)

Relevant Stocks

中國生物製藥(01177.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

中國生物製藥(01177.HK)TQG203上市申請獲得受理

Services

About Us

Agreement Statement